Cancer Treatment

138 Results

number of items to display at a time

Research

Nov 4, 2024

Variation in Communication of Side Effects in Prostate Cancer Treatment Consultations

Effective communication of treatment side effects (SE) is critical for shared decision-making (SDM) in localized prostate cancer. This article qualitatively characterizes how physicians communicate SE in consultations.
Research

Nov 4, 2024

Use of Persuasive Language in Communication of Risk During Prostate Cancer Treatment Consultations

Physician treatment preference may influence how risks are communicated in prostate cancer consultations. We identified persuasive language use when describing cancer prognosis, life expectancy, and side effects.
Research

Jun 12, 2024

Advancing the Development and Use of Diagnostic Target Product Profiles for Cancer

Our report provides a guide on how to develop robust, fit for purpose diagnostic Target Product Profiles (TPPs) for cancer, and support efforts to improve on earlier cancer detection.
Project

Jun 10, 2024

Developing target product profiles for innovation in cancer diagnosis

RAND Europe’s work is helping understand how diagnostic Target Product Profiles for cancer can be developed and the types of features they need to cover to be useful for innovators, payers and ultimately healthcare professionals and patients.
Research

Nov 6, 2023

Differences in Lymphoma Patients Between Chimeric Antigen Receptor T-cell Therapy Trials and the General Population

Effectiveness of CAR-T therapies in the general population of lymphoma patients may differ from effectiveness demonstrated in trials.
Research

Jun 14, 2023

Evaluation of Approaches to Recruitment of Racially and Ethnically Diverse Breast Cancer Patients from an Integrated Health Care Setting for Collection of Observational Social Network Data

We compared approaches to recruitment of diverse women with breast cancer in a study of social networks. Mailed letter was the best approach to recruit diverse women with breast cancer and collection of social network data.
Research

Jan 25, 2023

Cost-Effectiveness Analysis of CAR T-Cell Therapies Vs Antibody Drug Conjugates for Patients with Advanced Multiple Myeloma

In this analysis, we built a Monte Carlo Markov Chain microsimulation model using estimates and parameters from the evidence on standard treatment for multiple myeloma and chimeric antigen receptor T-cell therapies.
Research

Sep 21, 2022

Consensus-Based Guidance on Opioid Management in Individuals With Advanced Cancer-Related Pain and Opioid Misuse or Use Disorder

This qualitative study provides consensus-based guidance for clinicians and highlights research and policy gaps that warrant urgent attention to meet the needs of people with cancer-related pain and opioid misuse/use disorder.
Research

Sep 15, 2022

Enhancing Access to and Diversity in Cancer Clinical Trials Through a Financial Reimbursement Program: Protocol to Evaluate a Novel Program

We implemented a financial reimbursement and outreach program designed to increase the number and diversity of participants in cancer clinical trials at centers in Dallas, Houston, and Philadelphia.
Research

Sep 15, 2022

Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice

The barriers to the use of CAR-T therapy include complex logistics, manufacturing limitations, toxicity concerns, and financial burden. This review discusses solutions to overcome these barriers to make this therapy widely accessible.
Research

Aug 26, 2021

Narrative Review and Evidence Mapping: Proteomics for Cancer and Cardiovascular Disease

This report presents evidence supporting proteomic tests for cancer and cardiovascular disease currently approved in the United States and proteomic tests that may be available in the near term.
Research

Jun 17, 2021

B-cell Lymphoma and Non-Hodgkin's Lymphoma Treatment: How Do Participants of Chimeric Antigen Receptor T-cell (CAR-T) Therapy Research Studies Compare With Patients in the US Population?

Chimeric antigen receptor (CAR)-T-cell therapy appears to be a promising treatment for B-cell and non-Hodgkin's lymphoma. CAR-T therapy effectiveness in the general population of patients may differ from effectiveness demonstrated in trials.

Cancer Treatment

Cancer Treatment

Explore RAND’s Work on this Topic

Error

Variation in Communication of Side Effects in Prostate Cancer Treatment Consultations

Use of Persuasive Language in Communication of Risk During Prostate Cancer Treatment Consultations

Advancing the Development and Use of Diagnostic Target Product Profiles for Cancer

Developing target product profiles for innovation in cancer diagnosis

Differences in Lymphoma Patients Between Chimeric Antigen Receptor T-cell Therapy Trials and the General Population

Evaluation of Approaches to Recruitment of Racially and Ethnically Diverse Breast Cancer Patients from an Integrated Health Care Setting for Collection of Observational Social Network Data

Cost-Effectiveness Analysis of CAR T-Cell Therapies Vs Antibody Drug Conjugates for Patients with Advanced Multiple Myeloma

Consensus-Based Guidance on Opioid Management in Individuals With Advanced Cancer-Related Pain and Opioid Misuse or Use Disorder

Enhancing Access to and Diversity in Cancer Clinical Trials Through a Financial Reimbursement Program: Protocol to Evaluate a Novel Program

Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice

Narrative Review and Evidence Mapping: Proteomics for Cancer and Cardiovascular Disease

B-cell Lymphoma and Non-Hodgkin's Lymphoma Treatment: How Do Participants of Chimeric Antigen Receptor T-cell (CAR-T) Therapy Research Studies Compare With Patients in the US Population?

Oops! An unexpected error has occurred.

RAND Headquarters

Federally Funded Research Divisions

Social and Economic Policy Divisions

International

Cancer Treatment

Cancer Treatment

Explore RAND’s Work on this Topic

Error

Variation in Communication of Side Effects in Prostate Cancer Treatment Consultations

Use of Persuasive Language in Communication of Risk During Prostate Cancer Treatment Consultations

Advancing the Development and Use of Diagnostic Target Product Profiles for Cancer

Developing target product profiles for innovation in cancer diagnosis

Differences in Lymphoma Patients Between Chimeric Antigen Receptor T-cell Therapy Trials and the General Population

Evaluation of Approaches to Recruitment of Racially and Ethnically Diverse Breast Cancer Patients from an Integrated Health Care Setting for Collection of Observational Social Network Data

Cost-Effectiveness Analysis of CAR T-Cell Therapies Vs Antibody Drug Conjugates for Patients with Advanced Multiple Myeloma

Consensus-Based Guidance on Opioid Management in Individuals With Advanced Cancer-Related Pain and Opioid Misuse or Use Disorder

Enhancing Access to and Diversity in Cancer Clinical Trials Through a Financial Reimbursement Program: Protocol to Evaluate a Novel Program

Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice

Narrative Review and Evidence Mapping: Proteomics for Cancer and Cardiovascular Disease

B-cell Lymphoma and Non-Hodgkin's Lymphoma Treatment: How Do Participants of Chimeric Antigen Receptor T-cell (CAR-T) Therapy Research Studies Compare With Patients in the US Population?

Oops! An unexpected error has occurred.